Unknown

Dataset Information

0

A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media.


ABSTRACT: Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis media. A live vaccine candidate based on deletion of the signal recognition pathway component ftsY induced potent, serotype-independent protection against otitis media, sinusitis, pneumonia and invasive pneumococcal disease. Protection was maintained in animals coinfected with influenza virus, but was lost if mice were depleted of CD4(+) T cells at the time of vaccination. The live vaccine induced a strong serum IgG2a and IgG2b response that correlated with CD4(+) T-cell mediated class switching. Deletion of genes required for microbial adaptation to the host environment is a novel live attenuated vaccine strategy yielding the first experimental vaccine effective against pneumococcal otitis media.

SUBMITTER: Rosch JW 

PROVIDER: S-EPMC3936495 | biostudies-other | 2014 Jan

REPOSITORIES: biostudies-other

altmetric image

Publications

A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media.

Rosch Jason W JW   Iverson Amy R AR   Humann Jessica J   Mann Beth B   Gao Geli G   Vogel Peter P   Mina Michael M   Murrah Kyle A KA   Perez Antonia C AC   Edward Swords W W   Tuomanen Elaine I EI   McCullers Jonathan A JA  

EMBO molecular medicine 20140101 1


Acute otitis media (AOM) caused by Streptococcus pneumoniae remains one of the most common infectious diseases worldwide despite widespread vaccination. A major limitation of the currently licensed pneumococcal vaccines is the lack of efficacy against mucosal disease manifestations such as AOM, acute bacterial sinusitis and pneumonia. We sought to generate a novel class of live vaccines that (1) retain all major antigenic virulence proteins yet are fully attenuated and (2) protect against otitis  ...[more]

Similar Datasets

2013-01-01 | GSE41098 | GEO
| S-EPMC3584865 | biostudies-other
2013-01-01 | E-GEOD-41098 | biostudies-arrayexpress
| S-EPMC6248775 | biostudies-literature
| S-EPMC4380333 | biostudies-literature
| S-EPMC8096893 | biostudies-literature
| S-EPMC2643640 | biostudies-literature
| S-EPMC6537667 | biostudies-literature
| S-EPMC4272011 | biostudies-literature
| S-EPMC7934923 | biostudies-literature